The Crimson Circle: Why Investors Are Competing for Harvard Access

There is a quiet shift happening in venture right now, and it has nothing to do with louder decks or warmer intros. Capital is still moving. Conviction is still sharp. What is thinning out is access that actually compounds. Investors are no longer chasing ideas in isolation. They are competing for proximity to systems that consistently turn talent into outcomes. That tension lives at the center of the startup ecosystem, and it explains why certain rooms matter before the camera even turns on.

On February 12, 2026, Alumni Ventures and The Yard Ventures are not hosting a webinar to explain Harvard. Anyone with a browser can do that. This conversation exists because Harvard continues to pull gravity when markets get selective. 146,000+ ventures founded by alumni. $3.9T in annual revenue. 20.4M jobs supported globally. Those numbers come from an older impact study and still feel aggressive by today’s standards. The Harvard Innovation Labs alone have supported 6,500+ ventures and helped raise $9B+. The Office of Technology Development has converted academic output into $15.6B+ in capital. This is not mythology. It is repeatable infrastructure inside the startup ecosystem.

The Crimson Circle is virtual, but distance is not the point. The room fills with operators, allocators, and builders who understand that The Yard is not a brand exercise. It is a filter. 33,000+ alumni and friends. Pre-seed to later stage. Co-investing alongside Sequoia, a16z, Accel, and Khosla Ventures. Alumni Ventures does not lead rounds or take board seats. It shows up where momentum already exists and reinforces it. PitchBook keeps naming them the most active VC firm in the U.S. because activity, at scale, becomes its own form of signal inside the startup ecosystem.

Laura Bordewieck Rippy anchors the conversation with the steadiness of someone who has seen cycles break and reform. Managing Partner and Board Member at Alumni Ventures. Former CEO of Handango. Former Microsoft executive. Ranked #1 Woman Early-Stage Investor in 2025 and Top 25 overall. Laura Bordewieck Rippy brings pattern recognition, not posture. Luca Giani provides the counterweight. Senior Principal at Alumni Ventures. CEO of Ilios Therapeutics. Termeer Fellow. Blavatnik Fellow. A brain cancer survivor whose career focus on neurodegenerative disease is lived, not theoretical. This is what happens when capital meets consequence.

The Crimson Circle is not about getting access. It is about understanding why certain systems keep producing outcomes like Oura at an $11B valuation, SURGE Therapeutics with $58M raised, and Osmo with ~$130M raised. Harvard is not a logo in this context. It is a supply chain. Alumni Ventures is not selling proximity. It is curating signal. Investors who show up are not asking what is next. They are studying where gravity already lives inside the startup ecosystem, and deciding how close they need to stand.